Navigation Links
A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
Date:11/6/2007

REHOVOT, Israel, Nov. 6 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today that the primary end point and safety evaluation in the Phase II, Randomized Double Blind, Placebo-Controlled Dose-Escalating Study in Migraine patients was successfully completed. This event marks a major milestone in the development program of the compound MTR106 (tablet formulation of MTR104). MTR104 is a low molecular weight S-Alkylisothiouronium derivative.

This Phase II study was designed to assess the pharmacokinetics, safety and efficacy of MTR106 in female patients suffering from migraine without aura. The study population consisted of forty (40) female patients ranging from 22-57 years of age. The average duration of migraine attacks was 16.6 +/- 10 hours with a frequency of 2.8 +/- 1.3 attacks per month. The subjects were randomized in a ratio of 4:1: treatment to placebo respectively, constituting 4 groups of 10 patients each. Treatment arms of MTR106 or placebo were administered at escalating doses of 25, 50, 75 and 100 mg.

MTR106 was found to be safe and well tolerated. No serious adverse events occurred in the 4 studied doses and no symptoms related to chest pain or changes in heart rate or blood pressure were observed. The study results demonstrated that at 2 hours and at the 3rd and 4th hours post-treatment more patients treated with MTR106 had pain relief compared to those treated with placebo.

About Meditor Pharmaceuticals:

Meditor Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to the development and commercialization of proprietary products for the therapeutic management of acute and chronic hypotension and hypotension-related disorders. The lead development compound is a low molecular weight S-Alkylisothiouronium derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension. The clinical development program is focused on the development of lead compound MTR104 for the treatment of three main medical targets: MTR107 (i.v. formulation) for Intradialytic Hypotension, MTR106 (immediate release oral tablet formulation) for Migraine, and MTR105 (i.v. formulation) for the treatment of hypotension associated with cardiac (CABG) surgery. Meditor's patent portfolio provides the company with a strong proprietary position in the U.S. and worldwide. For more information on the company and its drug development activities, please visit http://www.meditorpharma.com

For all inquiries please contact Michael Schultz, R.Ph., VCG & Associates, Inc. at 636-329-1452 or Dr. David Coffin-Beach at (904) 501-5882


'/>"/>
SOURCE Meditor Pharmaceuticals Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... The OSHA Training Center at ... Center headquartered in Northern California, has issued an important reminder to employers to ... Employers with workers exposed to high temperatures should establish a complete heat ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
Breaking Medicine News(10 mins):